Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.12 USD | +0.65% | -11.61% | -57.26% |
May. 08 | Top Premarket Gainers | MT |
May. 08 | Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue | MT |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-57.26% | 132M | - | ||
+67.53% | 62.86B | B- | ||
-0.77% | 41.38B | B | ||
+45.66% | 40.38B | A | ||
-10.72% | 27.64B | C | ||
+13.30% | 26.46B | B- | ||
-22.79% | 18.9B | B | ||
+4.70% | 12.67B | B+ | ||
+24.10% | 12.27B | B+ | ||
+27.41% | 12.07B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RPTX Stock
- Ratings Repare Therapeutics Inc.